• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 20
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 20
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Newsmakers: Darren Shirley

    Are You Prepared for the 2023 DSCSA Deadline?

    Rethinking the Changing Role of the CRO

    23rd Annual Salary Survey

    Pharma 4.0 and the Modernizing Power of Digital Technology Transfer
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Pierre Fabre and Lonza Enter Manufacturing Agreement

    MasterControl and Elemental Machines Form Biomanufacturing Partnership

    Qosina Strengthens Aseptic Capabilities

    Charles River and Ziphius Vaccines to Manufacture saRNA-based Vaccine

    MilliporeSigma Opens $65M CDMO Facility for Cancer Therapies
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Pierre Fabre and Lonza Enter Manufacturing Agreement

    Qosina Strengthens Aseptic Capabilities

    MilliporeSigma Opens $65M CDMO Facility for Cancer Therapies

    Antheia Receives $40 million in Venture Debt Financing

    BioNTech Breaks Ground on First mRNA Vax Mfg. Facility in Africa
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Tubular Glass Primary Packaging for Pharmaceutical, Biotech and Diagnostic Containment

    How to Improve the Cold Chain System in Remote Locations

    Sentry Biopharma Services: Protecting Pharmaceutical Integrity

    Yourway to Build New Flagship European Depot

    Newsmakers: Darren Shirley
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    MasterControl and Elemental Machines Form Biomanufacturing Partnership

    Charles River and Ziphius Vaccines to Manufacture saRNA-based Vaccine

    Cullinan Oncology, Taiho to Develop & Commercialize CLN-081/TAS6417 in the U.S.

    BioNTech Breaks Ground on First mRNA Vax Mfg. Facility in Africa

    Tubular Glass Primary Packaging for Pharmaceutical, Biotech and Diagnostic Containment
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Should Remote Pharma GMP Audits End After COVID?

    Why is Big Pharma Increasingly Adopting 505(b)(2)?

    Sentry Biopharma Services: Protecting Pharmaceutical Integrity

    Selkirk Pharma Appoints New Head of Quality

    Be Safer by Doing Less: The Future of Zero Touch AE Case Processing
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Baxter BioPharma Solutions

    Quotient Sciences

    Societal CDMO

    CMC Pharmaceuticals

    Biosynth Carbosynth
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Baxter BioPharma Solutions

    Quotient Sciences

    Societal CDMO

    CMC Pharmaceuticals

    Biosynth Carbosynth
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • White Papers
    • Podcasts
    • Infographics
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Expert's Opinion

    CAR T for Large Tumors: The Next Frontier?

    Ryan Carpentier of Cryoport discusses the successes and the challenges these exciting new therapies present

    CAR T for Large Tumors: The Next Frontier?
    Related CONTENT
    • Mogene
    • Softweb Solutions
    • Continued and Consistent Investment in Manufacturing Facilities
    • Roche Wins Two Approvals for Cancer Drug Rozlytrek
    • Marker Therapeutics Appoints Regulatory Affairs VP
    Ryan Carpentier, Executive Director of Business Development at Cryoport09.10.19
    Traditional cancer treatments tend to be unprecise, the effect of which both healthy and cancerous cells are destroyed. Chemotherapy or radiation are like the military carpet bombing an area, and often cause considerable collateral damage. Additionally, traditional therapies have significant limitations in treating certain cancers and other genetic disorders. This has led to the development and implementation of an entirely new therapy class, known as advanced or regenerative therapies. One subtype of these therapies is a CAR T- cell therapy .

    What is a CAR T-cell therapy? In short, it is collecting, separating, and re-engineering a patients’ own immune cells to identify and then attack their cancer or other affliction. The goal of Chimeric antigen receptor (CAR) T-cell immunotherapy is to modify a patients T-cells to recognize cancer cells so that they can seek out and destroy them. Doctors harvest T cells from the patient, genetically alter them, then infuse the resulting CAR T-cells back into the patient to attack their tumors. CAR T-cells can be harvested from T cells in a patient's own blood (autologous) or derived from the T cells of a healthy donor (allogeneic). Both autologous and allogeneic CAR T therapies enable the immune system to attack only cancer cells and leave healthy cells unharmed.  One of the many advantages CAR T has over traditional treatments is that the therapies are administered over a short period of time with the goal of curing the disease rather than managing it. Early results demonstrate a significant and often curative result against hematologic cancers. There are two main side effects: cytokine release syndrome (CRS), affecting about 70-90% of patients; and, CAR T-cell-related encephalopathy syndrome (CRES). Either can start relatively soon after the treatment however, both have short durations and in the case of CRES (confusion and sometimes not being able to speak at all for a few days) are reversible or short-lived.

    In 2017, the FDA approved the first two CAR T therapies, one from Novartis, Kymriah (read more) and one from Gilead/Kite, Yescarta (read more).

    Given the early success of these two therapies, up to 94% remission rates in some cases, it is not surprising that there are currently over 240 active CAR T therapy clinical trials (read more). Both Kymriah and Yescarta are approved for targeting cancers that are hematologically based.  However, with new advances in biology and technology, scientists are starting to look at and target solid tumors, despite the inherent difficulties in employing CAR T therapies against solid tumors including tumor infiltration and addressing the tumor micro-environment, which can be detrimental to CAR T treatments. Applying CAR T treatments to much more common, and more commonly fatal, solid tumors is exciting and demonstrates that the space is not stationary and is advancing to address a wider application base in medicine. In fact, Gilead/Kite, on the back of the success of Yescarta, have been moving forward with a Phase III trial targeting solid tumors (https://clinicaltrials.gov/ct2/show/NCT03391466).

    TC Biopharm has two preclinical projects targeting solid tumors.  One targeting lung, breast, colorectal, liver and skin cancers; and, one targeting breast and ovarian cancer.  There are 270,000 new cases of breast cancer and 23,000 new cases of ovarian cancer per year in the United States alone. Another company investing heavily in finding effective CAR T therapies for solid tumors is Celyad. Celyad has reported some early success in trials targeting Colorectal cancer. These are just a few of the many examples of companies looking to expand the application of CAR T therapies as the science advances.
          
    A CAR T therapy is effectively a living drug. Each patient is unique, with many having compromised immune systems, or being inherently unstable and the quality of starting material is a key consideration that directly relates to the success or failure of a given cell therapy treatment regimen. Moreover, building out manufacturing capabilities to meet the variability from patient to patient, lot to lot, is a pressing and ongoing challenge. Building manufacturing capabilities for Phase I studies with less than 20 patients is not yet putting too much stress on the global cellular manufacturing capabilities. However, as therapies targeting large patient populations move through the drug development life cycle, overall contract manufacturing capacity and facility availability is going to be limiting and remains a critical consideration for biotechnology companies. 

    In addition to the manufacturing process, the ability to ensure Chain of compliance across the supply chain is an absolute necessity. Chain of Compliance, being similar to cGMP traceability standards in a manufacturing environment, will provide the additional safety and visibility these therapies require while in transit. Understanding how and what temperatures these therapies need to be transported to and from the point of care to the manufacturing site and back to the point of care is one of the unique challenges facing these companies. In many cases, these therapies are a patient’s last hope of receiving an effective treatment for their disease. Clinical studies have quickly shown whether a therapy is going to be safe and effective. Building out supply chain competencies may become the limiting factor when thinking about the addressable patient population.

    Based on the number of ind ’s currently on file, it’s highly likely that many of these therapies will be approved in the coming years. Former FDA Commissioner Scott Gottlieb anticipates more than 200 Investigational New Drug applications per year by 2020 for cell and gene therapy candidates. Based on those numbers, the FDA predicts, 10 to 20 approvals each year for these treatments by 2025 (read more). As a result of this forecast, the FDA has hired or will be hiring an additional 50 CAR T-specific reviewers.

    Finding a safer, more effective treatment for these conditions will be life changing for these patients and their families. An important take away is that with companies focusing on solid tumors, patients who only had ~six months left to live now have a possible alternative at a life-saving or life changing treatment.



     
    Ryan Carpentier is Cryport's Global Operations, Sales, and Business Development executive with proven success in creating processes, leading international initiatives, and generating millions of dollars in revenue and profit growth. He combines expert strategic planning and business planning skills with consistent success in leading operations, developing strategies, and delivering strong financial results and profitable growth. He is a dedicated, inspirational, intelligent, and positive leader able to inspire trust, clarify purpose, attract top talent, build cross-functional teams, mitigate risk, and dramatically improve operational performance.
    Related Searches
    • car t therapies
    • patients
    • Development
    • it
    Suggested For You
    Mogene Mogene
    Softweb Solutions Softweb Solutions
    Continued and Consistent Investment in Manufacturing Facilities Continued and Consistent Investment in Manufacturing Facilities
    Roche Wins Two Approvals for Cancer Drug Rozlytrek Roche Wins Two Approvals for Cancer Drug Rozlytrek
    Marker Therapeutics Appoints Regulatory Affairs VP Marker Therapeutics Appoints Regulatory Affairs VP
    Embracing Risk-Based Monitoring: The Pivotal Role of Tools and Technologies  Embracing Risk-Based Monitoring: The Pivotal Role of Tools and Technologies
    FDA Approves New Treatment for Drug-Resistant TB FDA Approves New Treatment for Drug-Resistant TB
    NIIMBL, FDA to Advance Innovation in Bio Manufacturing NIIMBL, FDA to Advance Innovation in Bio Manufacturing
    FDA Accepts RedHill Biopharma’s NDA for Talicia FDA Accepts RedHill Biopharma’s NDA for Talicia
    Gilead Sciences Gilead Sciences
    Syndax Pharma Gets IND Clearance for Leukemia Treatment Syndax Pharma Gets IND Clearance for Leukemia Treatment
    The FDA Gets Stricter with E&L Oversight, Can the Industry Keep Up? The FDA Gets Stricter with E&L Oversight, Can the Industry Keep Up?
    Cryoport, EVERSANA Enter Supply Chain Alliance Cryoport, EVERSANA Enter Supply Chain Alliance
    Biopharma Cold Chain Solutions Biopharma Cold Chain Solutions
    Sierra’s Momelotinib Granted FDA Fast Track Designation Sierra’s Momelotinib Granted FDA Fast Track Designation

    Related Buyers Guide Companies

    • Mogene

      ...
      Craig Morley, CEO 11.17.20

    • Softweb Solutions

      ...
      Micheal Jury, Marketing Manager 09.23.20

    • Biologics, Proteins, Vaccines | cGMP Manufacture | Drug Development
      Continued and Consistent Investment in Manufacturing Facilities

      Continued and Consistent Investment in Manufacturing Facilities

      As companies move their cell and gene therapies through the development process, supporting larger Phase III trials and commercial launches will be a challenge
      Ryan Carpentier, Executive Director of Business Development, Cryoport 09.23.19


    • Drug Development | Trials & Filings
      Roche Wins Two Approvals for Cancer Drug Rozlytrek

      Roche Wins Two Approvals for Cancer Drug Rozlytrek

      Becomes third tumor-agnostic drug to win FDA Approval
      08.16.19

    • Promotions & Moves
      Marker Therapeutics Appoints Regulatory Affairs VP

      Marker Therapeutics Appoints Regulatory Affairs VP

      Dr. Agopyan brings more than 15 years of industry knowledge in regulatory affairs and clinical development
      08.16.19

    Trending
    • Machine Learning-based Predictive Modeling: Notable Uses In Clinical Trials
    • Pierre Fabre And Lonza Enter Manufacturing Agreement
    • MilliporeSigma Opens $65M CDMO Facility For Cancer Therapies
    • 17th Annual Contracting & Outsourcing Conference Photos
    • Curia And Replicate Bioscience Enter SrRNA Collaboration
    Breaking News
    • Qosina Strengthens Aseptic Capabilities
    • Pierre Fabre and Lonza Enter Manufacturing Agreement
    • Charles River and Ziphius Vaccines to Manufacture saRNA-based Vaccine
    • MasterControl and Elemental Machines Form Biomanufacturing Partnership
    • MilliporeSigma Opens $65M CDMO Facility for Cancer Therapies
    View Breaking News >
    CURRENT ISSUE

    June 2022

    • Newsmakers: Darren Shirley
    • Are You Prepared for the 2023 DSCSA Deadline?
    • Rethinking the Changing Role of the CRO
    • 23rd Annual Salary Survey
    • Pharma 4.0 and the Modernizing Power of Digital Technology Transfer
    • CEO Spotlight: David Chang
    • Changes are on the Horizon for Single-use Systems in Pharmaceutical Manufacturing
    • CRO Industry Market Report
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Florida Food Products Acquires Javo
    Roquette Launches Nutralys Rice Protein
    New IADSA Chair Lauds Explorations of Supplementation in Healthcare Policy
    Coatings World

    Latest Breaking News From Coatings World

    The Southern Society for Coatings Technology's 84th Annual Technical Conference A Success
    PPG to Showcase Specialty Automotive, Aerospace Adhesives, Sealants at Adhesives & Bonding Expo
    PPG’s New Paint for a New Start Initiative to Transform 25-plus Schools Worldwide
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    MPO's Most Read Stories This Week—June 25
    Magnetic Insight Announces $17 Million in Series B Funding
    BreatheSuite Adds Brad Fluegel to its Board
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Pierre Fabre and Lonza Enter Manufacturing Agreement
    MasterControl and Elemental Machines Form Biomanufacturing Partnership
    Qosina Strengthens Aseptic Capabilities
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Benefit Exec Joins Madison Reed's Board
    Peroni & Ellis Brooklyn Launch Fragrance Collection Inspired by Italian Spritz Cocktails
    Rhode Is Trending for June, Trendalytics Says
    Happi

    Latest Breaking News From Happi

    Spate’s Nose for the Latest Beauty Trends Says The Skunk Stripe, Collagen Serum and Waterproof Eyeshadow are Top of Mind for Consumers this Summer
    A Suitor Emerges for Revlon, SK Capital’s New Dealmaker & P&G’s Indoor Air Quality Efforts
    Wonder Curl Wins GlossWire's GlossPitch Competition
    Ink World

    Latest Breaking News From Ink World

    Weekly Recap: INX’s VC Fund, Screen Industry and Ball Top This Week’s News
    British Coatings Federation Posts Online History
    Orion Announces Price Increases, Reduced Payment Terms
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    PCMC teams with IGT, Fujifilm makes big announcement and more
    Loftware recognized as 'AIDC Company of the Year'
    Schreiner MediPharm highlights sustainability of Needle-Trap technology
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Weekly Recap: SWM and Neenah Introduce Mativ Inc., Avgol honored for Biotransformation Technology & More
    Tranzonic Names VP of Supply Chain
    Ontex Climate Action Targets Approved by Science-Based Targets Initiative
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    ODT's Most-Read Stories This Week—June 25
    3Spine Inc. Receives IDE Approval for U.S. Pivotal Clinical Trial
    Volume-Based Procurement to Reduce Chinese Orthopedic Market Value
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Weekly Recap: eMagin, Applied Materials, and Schott Top This Week’s Stories
    NREL Names Jennifer Logan to Leadership Team as CFO
    National Grid Renewables Orders 2 GW of First Solar Modules

    Copyright © 2022 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login